Market closedNon-fractionalADR
Barinthus Biotherapeutics/BRNS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, formerly Vaccitech plc, is a clinical-stage biopharmaceutical company. It is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. It is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.
Ticker
BRNS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Didcot, United Kingdom
Employees
130
Website
www.barinthusbio.com
BRNS Metrics
BasicAdvanced
$75M
Market cap
-
P/E ratio
-$1.83
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$75M
52-week high
$5.10
52-week low
$1.64
Average daily volume
0.47
Financial strength
Current ratio
11.152
Management effectiveness
Return on assets (TTM)
-30.67%
Return on equity (TTM)
-34.88%
Return on investment (TTM)
-32.45%
Valuation
Price to revenue (TTM)
223.214
Price to book
0.433
Price to tangible book (TTM)
0.551
Growth
Revenue change (TTM)
-98.89%
Earnings per share change (TTM)
-337.94%
3-year revenue growth (CAGR)
-45.00%
What the Analysts think about BRNS
Analyst Ratings
Majority rating from 6 analysts.
BRNS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$15M
-10.47%
Profit margin
0.00%
NaN%
BRNS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.62
-$0.37
-$0.45
-$0.40
-
Expected
-$0.55
-$0.53
-$0.50
-$0.54
-$0.47
Surprise
13.35%
-30.19%
-9.89%
-26.47%
-
BRNS News
AllArticlesVideos
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
GlobeNewsWire·1 month ago
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
GlobeNewsWire·2 months ago
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Barinthus Biotherapeutics stock?
Barinthus Biotherapeutics (BRNS) has a market cap of $75M as of July 26, 2024.
What is the P/E ratio for Barinthus Biotherapeutics stock?
The price to earnings (P/E) ratio for Barinthus Biotherapeutics (BRNS) stock is 0 as of July 26, 2024.
Does Barinthus Biotherapeutics stock pay dividends?
No, Barinthus Biotherapeutics (BRNS) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Barinthus Biotherapeutics dividend payment date?
Barinthus Biotherapeutics (BRNS) stock does not pay dividends to its shareholders.
What is the beta indicator for Barinthus Biotherapeutics?
Barinthus Biotherapeutics (BRNS) does not currently have a Beta indicator.
Buy or sell Barinthus Biotherapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.